...industry will see the value of a lot of academic research and vice versa and this will build bridges and lead to some translational opportunities for academic researchers and industrial chemists as well.
(PRWEB UK) 23 October 2015
Future Medicinal Chemistry, a leading MEDLINE-indexed journal published by Future Science Group, has released a themed issue dedicated to providing coverage of the presentations that took place at the 2015 Academic Drug Discovery Conference (Cambridge, UK), organized by SelectBio. The themed issue, which consists of contributions from the conference speakers, offers a broad variety of content, from discussion on industry–academia alliances and novel drug discovery models to the latest research emerging from academia.
In the themed issue, Guest Editor and conference Chair John Spencer (University of Sussex, UK), provides an excellent summary of the presentations that were heard, and the main discussion points that arose at the meeting. The importance of bridging the translational research gap, dubbed the ‘the valley of death’, in addition to strategies towards implementing open innovation drug discovery platforms, emerged as key themes at the conference. This is reflected in the themed issue, which features expert commentaries on these areas from both Tim Hammonds (Cancer Research Technology Discovery Laboratories, UK) and Peter Nussbaumer (Lead Discovery Center GmbH, Germany), among others.
John Spencer commented that typically “academics tend to be able to take projects to a certain level, but never with the depth that you can achieve in an industrial setting, as academia just doesn’t have the infrastructure.” By highlighting the Academic Drug Discovery conference with this themed issue of the journal, Spencer hopes that “industry will see the value of a lot of academic research and vice versa and this will build bridges and lead to some translational opportunities for academic researchers and industrial chemists as well.”
Managing Commissioning Editor for Future Medicinal Chemistry, Hannah Coaker, commented: “This themed issue provides an excellent insight into academia’s growing role in the drug discovery arena and delivers key discussion on some of the major challenges associated with closing the gap between basic research and commercial application. With contributions from stakeholders, university researchers, and members of pharmaceutical and biotechnology organizations from around the world, this themed issue communicates the diverse perspectives of the many members involved in the drug discovery process.”
The themed issue can be viewed online - http://www.future-science.com/toc/fmc/7/14
In addition, you can watch a video interview with John Spencer, who speaks about the conference and themed issue, here.
About Future Medicinal Chemistry
Future Medicinal Chemistry provides monthly commentary and debate on the rapidly evolving field of medicinal chemistry. The MEDLINE-indexed journal showcases milestones in pharmaceutical R&D and features expert analysis of emerging research – from the identification of targets, through to the discovery, design, synthesis and evaluation of bioactive agents.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites includes Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. FSG has recently launched a partner site to Future Medicinal Chemistry, known as MedChemNet.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com